Natera (NASDAQ:NTRA) Stock: Insider Solomon Moshkevich Sells 1,010 Shares

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 1,010 shares of Natera stock in a transaction on Tuesday, October 27th. The stock was sold at an average price of $406.00, for a total transaction of $410,060.00. Following the transaction, the insider directly owned 105,904 shares in the company, valued at $42,997,024. This represents a 0.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Solomon Moshkevich also recently made the following trade(s):

• On Wednesday, October 28th, Solomon Moshkevich sold 1,162 shares of Natera stock. The stock was sold at an average price of $426.34, for a total transaction of $495,407.08.
• On Thursday, October 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $414.22, for a total transaction of $1,242,660.00.
• On Wednesday, September 2nd, Solomon Moshkevich sold 15,160 shares of Natera stock. The shares were sold at an average price of $326.89, for a total transaction of $4,955,652.40.
• On Tuesday, September 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $320.73, for a total transaction of $962,190.00.
• On Monday, August 3rd, Solomon Moshkevich sold 3,410 shares of Natera stock. The shares were sold at an average price of $265.58, for a total transaction of $905,627.80.

Natera Price Performance

Natera stock opened at $414.30 on Friday. Natera, Inc. has a 52 week low of $181.00 and a 52 week high of $437.41. The company’s 50 day moving average price is $377.06 and its two-hundred day moving average price is $266.44.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.02. The company had revenue of $752.75 million during the quarter, compared to analyst estimates of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%. Natera’s quarterly revenue was up 37.7% on a year-over-year basis. During the same period in the prior year, the company posted ($0.74) earnings per share. On average, analysts forecast that Natera, Inc. will post -1.14 EPS for the current fiscal year.

Key Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera’s stock momentum remains strong after reaching a new 52-week high of approximately $436, reflecting continued investor enthusiasm for its oncology testing business and Signatera growth prospects. Natera reaches a fresh 52-week high
• Positive Sentiment: Recent ESMO oncology data, including 25 company presentations and additional Signatera evidence, could support broader clinical adoption and future revenue growth. Natera presents 25 ESMO abstracts
• Neutral Sentiment: Natera is scheduled to report third-quarter 2026 results after the market closes on November 5. The report will provide a near-term catalyst focused on Signatera testing volumes, pricing, reimbursement and profitability. Natera third-quarter results announcement
• Negative Sentiment: Several insiders sold shares this week, including the CEO, CFO and other executives. The transactions totaled roughly 11,500 shares, but each sale was made under a pre-arranged Rule 10b5-1 plan to cover tax withholding on vested equity awards, making the signal less concerning than discretionary selling. Natera insider selling
• Negative Sentiment: Zacks warned that Natera may report another quarterly loss and does not currently show the usual combination of positive estimate revisions and earnings momentum associated with a likely beat. With the stock trading well above its long-term moving averages and some valuation analyses estimating substantial downside to fair value, investors may be taking profits ahead of earnings. Natera earnings outlook

Analyst Ratings Changes

A number of brokerages have recently issued reports on NTRA. Wells Fargo & Company lifted their price target on Natera from $220.00 to $284.00 and gave the company an “equal weight” rating in a research report on Friday, August 7th. Royal Bank Of Canada upped their price objective on shares of Natera from $350.00 to $460.00 and gave the stock an “outperform” rating in a research report on Friday, September 25th. Piper Sandler raised their target price on shares of Natera from $249.00 to $363.50 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. Stephens lifted their target price on shares of Natera from $305.00 to $350.00 and gave the company an “overweight” rating in a research report on Wednesday, August 12th. Finally, Zacks Research lowered shares of Natera from a “hold” rating to a “strong sell” rating in a research report on Friday, October 16th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $394.31.

Institutional Trading of Natera

Several institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new position in shares of Natera during the second quarter valued at $2,962,770,000. Arrowstreet Capital Limited Partnership increased its holdings in Natera by 1.0% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,191,732 shares of the medical research company’s stock worth $238,334,000 after buying an additional 11,793 shares in the last quarter. Maverick Capital Ltd. raised its position in Natera by 24.1% in the 1st quarter. Maverick Capital Ltd. now owns 1,171,633 shares of the medical research company’s stock worth $234,315,000 after buying an additional 227,605 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Natera by 10.7% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 833,376 shares of the medical research company’s stock worth $226,220,000 after buying an additional 80,440 shares during the last quarter. Finally, Bank of America Corp DE purchased a new position in Natera in the 2nd quarter worth about $199,960,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

About Natera

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.